Controversial new Alzheimer's drug gives patients in Maine hope
The treatment developed by Biogen could slow its progression, but health professionals and researchers are divided on whether the FDA was right to approve it.
More from Kennebec & Moose River Valleys
Kennebec Journal | Augusta
High school Alpine ski preview: Mt. Blue hopes to rule the slopes again
Kennebec & Moose River Valleys
•
Dec 5, 2022
Kennebec Journal | Augusta
U.S. offshore wind power gets jump-start with 1st lease auction
Kennebec & Moose River Valleys
•
Dec 5, 2022
Kennebec Journal | Augusta
2022-23 central Maine high school sports winter season previews
Kennebec & Moose River Valleys
•
Dec 5, 2022
Kennebec Journal | Augusta
Police use of weaponized robots in San Francisco renews debate over their use
Kennebec & Moose River Valleys
•
Dec 5, 2022
Kennebec Journal | Augusta
Connecticut hemp farmers want to be given preference for growing recreational marijuana
Kennebec & Moose River Valleys
•
Dec 5, 2022
Kennebec Journal | Augusta
Gov. Mills announces changes in communications office
Kennebec & Moose River Valleys
•
Dec 5, 2022
Kennebec Journal | Augusta
Judge denies legislators access to child protection files
Kennebec & Moose River Valleys
•
Dec 5, 2022
Kennebec Journal | Augusta
World Cup roundup: Croatia beats Japan in shootout to reach quarterfinals
Kennebec & Moose River Valleys
•
Dec 5, 2022